Meitheal Reveals Manufacturing Expansion Plans
Increasing Capacity To Produce Heparin Amid Supply Concerns
Meithal Pharmaceuticals has revealed future plans to expand its manufacturing capabilities as the US FDA approved a new vial manufacturing line that will double the firm’s capacity to supply the US market.
You may also be interested in...
Meitheal has launched enoxaparin in the US following its FDA approval towards the end of last year.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
Launching eight heparin vial presentations in the US is evidence of how injectables specialist Meitheal Pharmaceuticals intends to leverage the vertically-integrated production capacity of its Chinese parent group NKF.